In 2005, we embarked on an RO-1 funded project to build a quantitative multi-parameter protein-based model to predict recurrence in melanoma. The effort culminated in a Melanoma Recurrence Risk (MRR) test that was published in JCO in November 2009. The MRR test was based on 5 markers (two of which required subcellular localization) that could distinguish sentinel node negative patients with a 40% chance of recurrence from those with a 10% chance of recurrence in 8 years. Although this result is quite promising, was validated on 250 sentinel node patients, and has caught the interest of two diagnostic companies, the MMR has not been tested prospectively. Thus we are faced with a choice of """"""""locking"""""""" this test and beginning a prospective clinical trial or trying to improve the test, to get better separation between low risk and high risk disease. We have opted to let potential licensees (if there are any) test MMR version 1 while we move on to the development of version 2. Careful review of our work and the melanoma biomarker field has revealed about 75 very promising markers that we have not yet tested for potential inclusion into our MRR assay. Furthermore, our original assay was validated on a single cohort and has not been converted for use on standard melanoma biopsy tissue, since it was constructed and validated on TMAs. Here we propose construction and validation of a second version of the MMR. We will achieve this goal in three aims.
The first aim i s to construct a new training set and then test a series of new markers on this cohort. These new markers were either lost due to technical issues in our original version, or overlooked in the first round selections. A new model will be constructed based on the new marker data and internally validated. Then in aim 2 we will validate the cohort on two or three independent melanoma cohorts from at least one other institution.
In aim 3, working in parallel to the validation in aim 2, we will develop and standardize the MMR version 2 assay for use on whole sections typical of routine melanoma specimens. At the completion of this grant, we anticipate a MMR version 2 assay will be ready for application to patients and for a prospective diagnostic clinical trial.

Public Health Relevance

A key clinical problem in melanoma is the management of patients with melanoma greater than 0.8mm thick and no evidence of tumor in their sentinel nodes. Here we propose to build a model, based on multi-parameter, standardized protein expression in the primary melanoma, that can predict which of these patients have a high likelihood of recurrence and can subsequently be managed more aggressively.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Thurin, Magdalena
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Schools of Medicine
New Haven
United States
Zip Code
Viray, Hollis; Coulter, Madeline; Li, Kevin et al. (2014) Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol 22:363-71
How, Joan; Brown, Jason R; Saylor, Sasha et al. (2014) Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochem Cell Biol 142:195-204
Brown, Jason R; Wimberly, Hallie; Lannin, Donald R et al. (2014) Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 20:5995-6005
Rimm, David; Schalper, Kurt; Pusztai, Lajos (2014) Unvalidated antibodies and misleading results. Breast Cancer Res Treat 147:457-8
Rothberg, Bonnie E Gould; Rimm, David L (2014) Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol 1102:227-58
Viray, Hollis; Bradley, William R; Schalper, Kurt A et al. (2013) Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med 137:1063-73
Velcheti, Vamsidhar; Rimm, David L; Schalper, Kurt A (2013) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 8:803-5
Hanna, Jason A; Wimberly, Hallie; Kumar, Salil et al. (2012) Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 52:235-45
Hanna, Jason A; Hahn, Lewis; Agarwal, Seema et al. (2012) In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 92:1390-7
Gould Rothberg, Bonnie E; Rimm, David L (2010) Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 130:1971-87

Showing the most recent 10 out of 22 publications